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Objectives The study aim was to determine the prognostic value of a multimarker strategy for risk-assessment in patients
presenting to the emergency department (ED) with dyspnea.
Background Combining biomarkers with different pathophysiological backgrounds may improve risk stratification in dyspneic
patients in the ED.
Methods The study prospectively investigated the prognostic value of the biomarkers N-terminal pro–B-type natriuretic
peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-sensitivity C-reactive
protein (hs-CRP), and Galectin-3 (Gal-3) for 90-day mortality in 603 patients presenting to the ED with dyspnea
as primary complaint.
Results hs-CRP, hs-cTnT, Cyst-C, and NT-proBNP were independent predictors of 90-day mortality. The number of ele-
vated biomarkers was highly associated with outcome (odds ratio: 2.94 per biomarker, 95% confidence interval
[CI]: 2.29 to 3.78, p  0.001). A multimarker approach had incremental value beyond a single-marker ap-
proach. Our multimarker emergency dyspnea-risk score (MARKED-risk score) incorporating age 75 years, sys-
tolic blood pressure 110 mm Hg, history of heart failure, dyspnea New York Heart Association functional class
IV, hs-cTnT 0.04 g/l, hs-CRP 25 mg/l, and Cys-C 1.125 mg/l had excellent prognostic performance (area
under the curve: 0.85, 95% CI: 0.81 to 0.89), was robust in internal validation analyses and could identify pa-
tients with very low (3 points), intermediate (3, 5 points), and high risk (5 points) of 90-day mortality
(2%, 14%, and 44% respectively; p  0.001).
Conclusions A multimarker strategy provided superior risk stratification beyond any single-marker approach. The MARKED-
risk score that incorporates hs-cTnT, hs-CRP, and Cys-C along with clinical risk factors accurately identifies pa-
tients with very low, intermediate, and high risk. (J Am Coll Cardiol 2012;60:1668–77) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.040Acute onset or progressive increase in dyspnea can indicate
both harmless as well as highly lethal conditions (1,2).
Therefore, accurate risk assessment is important in this
patient group. Especially short-term risk stratification can
help to triage which patients require particular and imme-
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October 23, 2012:1668–77 Multimarker Score in Emergency Department Dyspneadyspnea has been developed (6) that takes into account
N-terminal pro–B-type natriuretic peptide (NT-proBNP): 1
of the most studied and clinically implemented biomarkers in
acute dyspnea (7). However, many more biomarkers have
emerged over the last years and they are suggested to
provide additional or superior prognostic information in
patients with dyspnea and acute heart failure (8–13). More-
over, a single biomarker may not be sufficient to provide
adequate risk assessment (14). Most studies thus far have
looked into acute heart failure alone rather than acute or
recent onset dyspnea (10–12,15) and studies that have
assessed the prognostic value of multiple biomarkers in
acute dyspnea have compared biomarkers rather than exam-
ine the impact of combining them (8,9). We hypothesize
that prediction of risk in patients with dyspnea at the
emergency department (ED) could be improved by com-
bining multiple biomarkers (1,2). We studied NT-proBNP,
high-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C
(Cys-C), high-sensitivity C-reactive protein (hs-CRP), and
Galectin-3 (Gal-3) because these are established biomarkers
with different pathophysiological backgrounds (i.e., myocyte
stretch, myocardial damage, and renal function, inflam-
mation, and fibrosis, respectively) and investigated the
value of a multimarker strategy for risk assessment in
dyspnea at the ED.
Methods
Study population and design. Between June 2007 and
October 2009, patients who presented to the cardiology ED
of the Maastricht University Medical Center with dys-
pnea—either at rest or during physical activity—were con-
secutively enrolled in this prospective study. Patients were
eligible if they were 18 years old and dyspnea was their
ain complaint. Patients referred for therapeutic treatment
r patients that required immediate therapeutic action (e.g.,
ercutaneous coronary intervention or electrical or chemical
ardioversion) and patients with dyspnea resulting from
hest trauma were excluded. Also, not all physicians in our
epartment participated in the trial and patients that were
een by nonparticipating physicians were not included. All
atient characteristics were based on clinical chart review.
eft ventricular ejection fraction was obtained from echo-
ardiography when available within a range of 1 year before
resentation to 1 month after presentation. Presence of
oronary artery disease was defined as having a history of
oronary artery bypass grafting, percutaneous coronary in-
ervention, acute myocardial infarction, or obstructive cor-
nary artery disease on coronary angiography or computed
omography angiography. Patients were followed for 1 year.
ollow-up data were obtained via chart review and, if
ecessary, from the general practitioner or by enquiry of the
unicipal register. Primary outcome measure was 90-day
ll-cause mortality. Secondary outcome measures encom-
assed 90-day cardiovascular mortality as well as in-
ospital, 30-day, and 1-year all-cause and cardiovascularmortality. All investigational
procedures involved in this study
have been approved by the insti-
tutional review board (Medical
Ethical Committee, Maastricht
University Medical Center) and
comply with the Declaration of
Helsinki.
Biochemical analysis. Blood
samples were obtained on patient
arrival at the ED. Measurements
of several laboratory parameters
(e.g., NT-proBNP, conventional
cTnT, blood urea nitrogen (BUN),
hemoglobin, creatinine) were
performed immediately after
blood collection. Excess of col-
lected serum sample was frozen
and aliquots were stored at
–80°C until analyzed. hs-cTnT,
hs-CRP, Cys-C, and Gal-3 con-
centrations were measured in
2010 (1 freeze-thaw cycle). De-
tailed information about the as-
says and their performance char-
acteristics is provided in Online
Table 1 (10,16–21).
Statistical analysis. Data are presented as frequencies,
mean  SD, or median (interquartile range). Comparisons
between groups were performed using chi-square tests for
categorical data and 1-way analysis of variance or Kruskal-
Wallis H test for continuous data, as appropriate. Receiver-
operating characteristic curve analysis was used to assess
prognostic accuracy of biomarkers and to determine opti-
mum cutoff points (i.e., maximizing both sensitivity and
1-specificity) of continuous variables for predicting 90-day
mortality. Cutoff points were rounded off to make them
clinically meaningful. Spearman’s rank correlations were
used to test correlations between biomarkers.
Logistic regression analysis was performed to test the
association between biomarkers and 90-day mortality. Mul-
tivariable analysis was performed for clustered variables (i.e.,
for clinical covariates) and laboratory findings separately.
We included variables that were univariably associated with
90-day mortality (stepwise with p  0.1 as the cutoff for
entry). Thus, in a first step, a final clinical model and a
separate final biomarker panel were established from mul-
tivariable analysis. In a second step, the final biomarker
panel was added in a stepwise fashion to the final clinical
model, which resulted in the final prediction model. We
checked for collinearity and interactions among covariates
and found none of significance. Model accuracy, calibration,
and discrimination were evaluated as recently suggested (22)
by: 1) C-statistic, a measure of the area under the curve
(AUC); 2) the Hosmer-Lemeshow statistic; 3) integrated
Abbreviations and
acronyms
AUC  area under the
curve
BUN  blood urea nitrogen
CI  confidence interval
Cys-C  Cystatin-C
ED  emergency
department
Gal-3  Galectin-3
HF  heart failure
hs-CRP  high-sensitivity
C-reactive protein
hs-cTnT  high-sensitivity
cardiac troponin T
IDI  integrated
discrimination improvement
MARKED  multimarker
emergency dyspnea
NRI  net reclassification
index
NT-proBNP  N-terminal
pro–B-type natriuretic
peptidediscrimination improvement (IDI); and 4) net reclassifica-
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Multimarker Score in Emergency Department Dyspnea October 23, 2012:1668–77tion index (NRI). Risk categories of 2%, 2 to 15%, and
15% were used for calculation of the NRI (23).
Independent predictive variables in the final prediction
model formed the basis for our risk score. When simplifying
the score, a loss in AUC of1% was not accepted. The risk
score was internally validated by cross-validation (90% of
original sample, 10 replications) and by nonparametric
bootstrapping (1,000 resamples using random sampling
with replacement), as proposed (24).
The PRIDE (ProBNP Investigation of Dyspnea in the
ED) mortality score was calculated as proposed (6). The
additional predictive value of the final biomarker panel on
top of the PRIDE mortality score (6) was investigated for
both 90-day and 1-year mortality in a multivariable logistic
regression model and tested by C-statistic, NRI, and IDI.
Kaplan-Meier curve plots were estimated and compared
by the log-rank test. For time-dependent analysis, data were
censored at the time of last contact. Tests were 2-sided with
a level of significance of p  0.05. Calculations were done
sing SPSS version 16.0 (SPSS Inc., Chicago, Illinois) and
igmaplot version 12.0 (Systat Software Inc., Chicago,
llinois).
esults
aseline characteristics. Between June 2007 and October
009, 1,477 patients presented with dyspnea to the ED.
ne hundred and four patients (7%) were excluded because
yspnea was not their main complaint and 106 (7%)
atients were excluded because they required immediate
herapeutic action. Of the remaining 1,267 eligible patients,
23 (41%) were admitted during working hours of nonpar-
icipating physicians. In 141 (11%) patients at least 1
aseline biomarker concentration was missing. Baseline
haracteristics of the final study population of 603 patients
re depicted in Table 1. Patients were elderly, with a median
ge of 75 years, 55% were male, more than one-third had a
istory of heart failure (HF), and almost one-half had a
istory of coronary artery disease. A large proportion had
ardiovascular risk factors such as hypertension (70%) and
iabetes mellitus (29%). Almost 40% had dyspnea at rest at
resentation. Final diagnosis at the ED was most commonly
cute decompensated heart failure (i.e., 57%). A noncardiac
iagnosis was made in 28% of the patients.
Eligible patients that were not included (n  664) were
ounger (72 vs. 75 years of age, p  0.001) compared with
ncluded patients, but no difference in gender or final
iagnosis was observed. Importantly, patients that were not
ncluded due to missing biomarkers (n  141) did not differ
egarding age, gender, or final diagnosis compared with
atients included.
PREDICTION OF OUTCOME. More than half of the patients
(n 347, 58%) were admitted to the hospital subsequent to
their presentation on the ED. The 90 day follow-up was
completed in all patients. After 90 days, 78 patients (13%)
had died, 58 (74%) from cardiovascular causes. At a median sfollow-up of 365 days (interquartile range: 266 to 365), 145
patients (24%) had died, 100 (69%) from cardiovascular
causes.
All biomarkers were highly associated with 90-day mor-
tality (Table 2) and had comparable AUCs for the predic-
tion of 90-day mortality, ranging from 0.73 to 0.75 (p 0.5
for all comparisons) (Online Table 2). Cutoff values deter-
mined from receiver-operating characteristic curve analyses
were 4,500 pg/ml for NT-proBNP, 0.04 g/l for hs-cTnT,
.125 mg/l for Cys-C, 25 mg/l for hs-CRP, and 25 g/l for
al-3. Biomarkers were significantly correlated, with the
trongest correlation being present between Cys-C and
al-3 (r  0.70, p  0.001) followed by NT-proBNP and
s-cTnT (r  0.55, p  0.001) (Online Table 3).
In categorical multivariable analysis including all labora-
ory findings, NT-proBNP, hs-cTnT, hs-CRP, and Cys-C
emained independently associated with 90-day mortality
Table 2) and thus formed the final biomarker panel. The
ombination of these 4 biomarkers (i.e., hs-cTnT, hs-CRP,
ys-C, and NT-proBNP) reached a high predictive accu-
acy with an AUC for 90-day mortality of 0.83 (95%
onfidence interval [CI]: 0.78 to 0.87) and the number of
iomarkers elevated (i.e., none, 1, 2, 3, or 4) was strongly
ssociated with increased risk of 90-day mortality (odds
atio [OR]: 2.94 per elevated biomarker, 95% CI: 2.29 to
.78, Wald 71.0, p  0.001) with 90-day mortality rates of
.7%, 4.5%, 10.4%, 25.2%, and 49.1%, respectively (p 
.001). The gradual increase in 90-day mortality rate with
ncreasing number of biomarkers elevated was retained in
ubgroup analyses of patients with versus without acute
ecompensated heart failure and renal dysfunction (Fig. 1).
ach specific combination of either 2 or 3 biomarkers (e.g.,
T-proBNP  hs-cTnT vs. hs-CRP  Gal-3) had similar
0-day mortality rates (p  0.1 for all comparisons). The
-year mortality rate also showed a significant increment
ith increasing number of biomarkers elevated (6.8%,
1.5%, 23.2%, 45.5%, and 61.8%, p  0.001), which is
hown in Figure 2A.
Following from categorical multivariable analysis on clin-
cal risk factors, age, gender, HF history, dyspnea New York
eart Association functional class, and systolic blood pres-
ure formed the final clinical model (Table 2). When
orrecting the final biomarker panel for the final clinical
odel, hs-cTnT, hs-CRP, and Cys-C remained indepen-
ent prognostic biomarkers whereas NT-proBNP was
ropped (Table 2). The final prognostic model therefore
onsisted of the final clinical model plus hs-cTnT, hs-CRP,
nd Cys-C and reached a C-statistic of 0.86 (0.82 to 0.90)
ith excellent calibration (Hosmer-Lemeshow p  0.78)
Table 3) and significantly better model performance than
ingle-marker models (NRI 13%, p  0.008 and IDI 5%,
 0.001 compared with the model with clinical risk
actors and hs-CRP alone, p  0.01). Exclusion of patients
ith clinical signs of infection did not alter results (data nothown).
Baseline Characteristics by Number of Elevated BiomarkersTable 1 Baseline Characteristics by Number of Elevated Biomarkers
Overall No Marker Elevated 1 Marker Elevated 2 Markers Elevated 3 Markers Elevated 4 Markers Elevated
p ValueValue n Value n Value n Value n Value n Value n
Demographics
Age, yrs 75 12 603 69 14 148 74 12 156 78 9 125 78 12 119 81 7 55 0.001
Sex, male 334 (55.4%) 603 80 (54.1%) 148 78 (50.0%) 156 67 (53.6%) 125 74 (62.2%) 119 35 (63.6%) 55 0.211
Medical history
Heart failure 210 (34.8%) 603 39 (26.4%) 148 45 (28.8%) 156 45 (36.0%) 125 49 (41.2%) 119 32 (58.2%) 55 0.001
Ischemic etiology 138 (65.7%) 210 21 (53.8%) 39 35 (77.8%) 45 27 (60.0%) 45 34 (69.4%) 49 21 (65.6%) 32 0.178
CAD 280 (46.4%) 603 64 (43.2%) 148 76 (48.7%) 156 49 (39.2%) 125 61 (51.3%) 119 30 (54.5%) 55 0.189
Diabetes mellitus 171 (29.2%) 585 31 (21.2%) 146 46 (30.3%) 152 38 (31.4%) 121 39 (34.5%) 113 17 (32.1%) 53 0.159
Atrial fibrillation 187 (31.1%) 601 41 (27.7%) 148 44 (28.2%) 156 37 (29.8%) 124 45 (38.1%) 118 20 (36.4%) 55 0.294
COPD 133 (22.2%) 600 29 (19.7%) 147 36 (23.2%) 155 25 (20.0%) 125 34 (28.6%) 119 9 (16.7%) 54 0.317
Hypertension 345 (70.4%) 490 79 (67.5%) 117 94 (74.0%) 127 74 (74.7%) 99 65 (64.4%) 101 33 (71.7%) 46 0.410
LVEF, % 45 (28–59) 351 50 (35–60) 86 45 (30–60) 91 45 (25–58) 67 35 (25–50) 74 40 (26–48) 33 0.001
Signs and symptoms
Dyspnea at rest 230 (38.1%) 603 47 (31.8%) 148 58 (37.2%) 156 42 (33.6%) 125 57 (47.9%) 119 26 (47.3%) 55 0.033
Systolic BP, mm Hg 137.0 28.9 573 145.0 27.3 141 140.0 28.5 146 137.0 28.0 119 134.0 30.0 117 124.0 29.3 50 0.001
Diastolic BP, mm Hg 74.7 17.4 573 80.5 17.2 141 75.5 18.0 146 73.1 17.1 119 71.3 15.6 117 68.3 17.1 50 0.001
Heart rate, beats/min 91.6 28.3 600 88.6 25.6 146 89.6 27.0 156 93.7 31.5 125 93.5 28.9 119 96.6 29.2 54 0.925
QRS duration 108.0 31.3 539 103.0 28.2 131 106.0 30.1 146 111.0 35.9 107 112.0 30.6 109 116.0 31.0 46 0.030
Laboratory findings
Hemoglobin, g/dl 12.7 2.1 598 13.7 1.8 145 12.9 2.1 155 12.2 1.9 125 12.1 2.1 118 11.9 1.9 55 0.001
Creatinine, mg/dl 1.3 (1.0–1.7) 603 1.0 (0.9–1.1) 148 1.2 (1.0–1.4) 156 1.3 (1.1–1.7) 125 1.7 (1.2–2.4) 119 2.0 (1.5–2.8) 55 0.001
Blood urea nitrogen, mg/dl 22.4 (17.1–35.3) 602 17.1 (13.2–21.0) 148 20.4 (17.1–28.0) 156 25.2 (18.8–35.0) 124 33.3 (21.6–51.8) 119 45.1 (34.5–67.5) 55 0.001
hs-CRP, mg/l 13.0 (3.9–35.3) 603 3.76 (1.71–8.16) 148 9.22 (3.39–24.38) 156 16.80 (5.39–40.9) 125 24.60 (8.26–66.40) 119 72.5 (37.70–137.00) 55 0.001
hs-cTnT, g/l 0.031 (0.016–0.058) 603 0.014 (0.007–0.021) 148 0.023 (0.013–0.034) 156 0.036 (0.024–0.062) 125 0.063 (0.044–0.109) 119 0.096 (0.057–0.227) 55 0.001
Cystatin-C, mg/l 1.14 (0.89–1.63) 603 0.85 (0.74–0.98) 148 1.09 (0.85–1.40) 156 1.24 (1.07–1.67) 125 1.62 (1.20–2.34) 119 1.79 (1.47–2.57) 55 0.001
NT-proBNP, pg/ml 3,110 (907–8,390) 603 826 (180–2,091) 148 1,555 (712–3,547) 156 4,864 (2,127–8,352) 125 9,347 (4,924–15,907) 119 17,601 (9,805–25,085) 55 0.001
Galectin-3, g/l 23 (17–32) 603 17 (14–20) 148 21 (17–27) 156 24 (19–32) 125 30 (24–39) 119 36 (30–54) 55 0.001
Final diagnosis
ADHF 342 (56.7%) 603 50 (33.8%) 148 74 (47.4%) 156 81 (64.8%) 125 94 (79.0%) 119 43 (78.2%) 55 0.001
ACS 46 (7.6%) 603 14 (9.5%) 148 15 (9.6%) 156 11 (8.8%) 125 0 (0%) 119 6 (10.9%) 55 0.014
Rhythm/conduction
disturbances
45 (7.5%) 603 10 (6.8%) 148 12 (7.7%) 156 9 (7.2%) 125 11 (9.2%) 119 3 (5.5%) 55 0.910
PD 30 (5.0%) 603 9 (6.1%) 148 11 (7.1%) 156 4 (3.2%) 125 5 (4.2%) 119 1 (1.8%) 55 0.413
Other 50 (8.3%) 603 14 (9.5%) 148 19 (12.2%) 156 10 (8.0%) 125 6 (5.0%) 119 1 (1.8%) 55 0.089
No pathology 90 (14.9%) 603 51 (34.5%) 148 25 (16.0%) 156 10 (8.0%) 125 3 (2.5%) 119 1 (1.8%) 55 0.001
Medical treatment
Diuretics 356 (59.9%) 594 64 (43.8%) 146 90 (58.8%) 153 78 (63.9%) 122 84 (71.2%) 118 40 (72.7%) 55 0.001
ACEi or ARB 337 (56.7%) 594 82 (56.2%) 146 93 (60.8%) 153 68 (55.7%) 122 67 (56.8%) 118 27 (49.1%) 55 0.663
Beta-blockers 330 (55.6%) 594 79 (54.1%) 146 84 (54.9%) 153 64 (52.5%) 122 67 (56.8%) 118 36 (65.5%) 55 0.578
Aldosterone antagonists 48 (8.1%) 594 8 (5.5%) 146 12 (7.8%) 153 13 (10.7%) 122 8 (6.8%) 118 7 (12.7%) 55 0.367
OAC 222 (37.4%) 594 48 (32.9%) 146 56 (36.6%) 153 42 (34.4%) 122 53 (44.9%) 118 23 (41.8%) 55 0.279
Digitalis 77 (13.0%) 594 13 (8.9%) 146 19 (12.4%) 153 12 (9.8%) 122 23 (19.5%) 118 10 (18.2%) 55 0.061
Values are mean  SD, n (%), or median (interquartile range).
ACEi  angiotensin-converting enzyme inhibitor; ACS  acute coronary syndrome; ADHF  acute decompensated heart failure; ARB  angiotensin II receptor blocker; BP  blood pressure; CAD  coronary artery disease; COPD  chronic obstructive pulmonary disease;
hs-CRP  high-sensitivity C-reactive protein; hs-cTnT  high-sensitivity cardiac troponin T; LVEF  left ventricular ejection fraction; NT-proBNP  N-terminal pro–B-type natriuretic peptide; OAC  oral anticoagulation; PD  pulmonary disease.
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Multimarker Score in Emergency Department Dyspnea October 23, 2012:1668–77MULTIMARKER EMERGENCY DYSPNEA RISK SCORE. Result-
ing from the final prognostic model for 90-day mortality, a
risk score was established. Simplifying the risk score by
giving each factor the same weight (1 point) and by
excluding the weakest factor (i.e., gender) did not change
performance of the score. Excluding any of the other
variables did reduce the AUC by1%. Final variables in the
ultimarker emergency dyspnea risk score (MARKED-risk
core) therefore consisted of: age 75 years, history of HF,
yspnea at rest, systolic blood pressure 110 mm Hg,
s-CRP 25 mg/l, hs-cTnT 0.04 g/l, and Cys-C
1.125 mg/l. The score showed excellent discrimination
AUC: 0.85, 95% CI: 0.81 to 0.89) and predicted mortality
isk closely resembled observed mortality risk (Online Fig. 1).
nternal validation by means of cross-validation (mean
UC: 0.85, 95% CI: 0.81 to 0.89) and bootstrapping
AUC: 0.85, 95% CI: 0.81 to 0.89) showed that the score’s
erformance was robust. Ninety-day mortality rates gradu-
lly increased per MARKED-risk score point (Fig. 3).
The score was categorized into low- (2 points),
Association of Clinical Characteristics and Biomarkers With 90-DaTable 2 Association of Clinical Characteristics and Biomarkers
Univariable Analysis
Wald Test OR 95% CI p Valu
Clinical variables
Demographics
Age 75 yrs 17.7 3.78 2.03–7.03 0.001
Male 5.6 1.84 1.11–3.05 0.02
Medical history
History of heart failure 19.0 2.98 1.83–4.84 0.001
Ischemic etiology of heart
failure
15.8 2.75 1.67–4.53 0.001
CAD 6.7 1.90 1.17–3.09 0.009
Diabetes mellitus 0.09 0.92 0.54–1.57 0.76
Atrial fibrillation 4.1 1.66 1.02–2.71 0.04
COPD 1.2 1.36 0.79–2.34 0.27
Hypertension 1.9 0.72 0.44–1.15 0.17
Signs and symptoms at
presentation
Dyspnea NYHA functional
class IV
10.6 2.22 1.37–3.59 0.001
Systolic BP, 110 mm Hg 22.8 3.80 2.20–6.57 0.001
Heart rate, 100 beats/min 1.8 1.40 0.86–2.29 0.18
QRS duration 100 ms 3.9 1.62 1.01–2.61 0.05
Laboratory findings
Hemoglobin 12 g/dl 14.1 2.52 1.56–4.08 0.001
Creatinine  1.4 mg/dl 20.1 3.07 1.88–5.01 0.001
Blood urea nitrogen 28 mg/dl 34.2 4.52 2.73–7.50 0.001
NT-proBNP 4500 pg/ml 32.2 4.56 2.70–7.71 0.001
hs-cTnT 0.04 g/l 41.9 5.95 3.47–10.21 0.001
hs-CRP 25 mg/l 39.9 5.14 3.10–8.55 0.001
Cystatin-C 1.125 mg/l 30.4 5.71 3.08–10.62 0.001
Galectin-3 25 g/l 37.8 5.57 3.22–9.62 0.001
Variables entered into multivariable analysis (cutoff for entry p  0.1). †Variables that remaine
remained significant in multivariable analysis including laboratory findings and were added stepw
CI  confidence interval; NYHA  New York Heart Association functional class; OR  odds ratintermediate- (3 to 5 points), and high-risk categories (6oints). Figure 2B shows the Kaplan-Meier curve for
all-cause mortality by MARKED-risk score category and
Table 4 depicts secondary endpoint rates per MARKED-
risk score category. The mortality risk of nonadmitted
versus admitted patients was similar within each risk score
category (low: 1% vs. 2%, p  0.66; intermediate: 11% vs.
15%, p  0.30; high: 39% vs. 46%, p  0.64). In addition,
9% of the patients that were discharged from the ED were
in the high-risk category and 39% of these patients died
within 90 days, underscoring the clinical prognostic uncer-
tainty and the potential importance of the MARKED-risk
score in this setting.
Added value of biomarkers on top of PRIDE mortality
score. We evaluated the incremental value of the biomark-
ers Cys-C, hs-cTnT, and hs-CRP with the PRIDE mor-
tality score (6), which includes clinical risk factors and
NT-proBNP. For 90-day mortality, the combination of the
3 biomarkers significantly improved the PRIDE mortality
score as depicted by an increase in C-statistic from 0.75
(95% CI: 0.69 to 0.80) to 0.85 (95% CI: 0.81 to 0.89, p 
rtality90-Day Mortality
Multivariable Clustered Analysis
(Clinical/Laboratory)
Multivariable Analysis Combining
Clinical and Laboratory
ald OR 95% CI p Value Wald OR 95% CI p Value
7.3 4.01 2.08–7.71 0.001† 5.3 2.32 1.14–4.75 0.02
4.9 1.86 1.08–3.19 0.03† 1.69 1.48 0.82–2.65 0.19
1.5 2.43 1.45–4.07 0.001† 9.8 2.48 1.40–4.37 0.002
— — — — — — — —
— — — — — — — —
— — — — — — — —
— — — — — — — —
— — — — — — — —
— — — — — — — —
9.5 2.27 1.35–3.83 0.02† 8.8 2.37 1.34–4.19 0.003
0.0 3.92 2.16–7.11 0.001† 9.4 2.76 1.44–5.27 0.002
— — — — — — — —
— — — — — — — —
— — — — — — — —
— — — — — — — —
— — — — — — — —
6.2 2.10 1.17–3.77 0.01‡ — — — —
1.9 2.85 1.57–5.17 0.001‡ 11.5 2.84 1.55–5.18 0.001
4.1 3.88 2.26–6.66 0.001‡ 21.3 3.88 2.18–6.89 0.001
3.7 3.51 1.80–6.82 0.001‡ 7.0 2.58 1.28–5.29 0.008
— — — — — — — —
cant in multivariable analysis including clinical risk factors (final clinical model). ‡Variables that
he final clinical model.
r abbreviations as in Table 1.y MoWith
e W
 1
 1



 2




 1
 2
 1

d signifi0.001), an NRI of 33% (p  0.001), and an IDI of 14%
N
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PRIDE mortality score was 0.72 (95% CI: 0.68 to 0.77),
which improved to 0.79 (95% CI: 0.74 to 0.83, p  0.001)
by addition of hs-cTnT, hs-CRP, and Cys-C.
Discussion
We investigated 5 biomarkers (hs-cTnT, hs-CRP, Gal-3,
Cys-C, and NT-proBNP) with a distinct pathophysiologi-
cal background for short-term risk stratification in 603
patients with dyspnea presenting to the ED. hs-cTnT,
hs-CRP, Cys-C, and NT-proBNP were independent pre-
dictors of 90-day all-cause mortality and risk increased
substantially as more biomarkers were elevated above the cut
point. Moreover, we present a simple and straightforward
score for short-term risk stratification based on biomarkers
in combination with clinical risk factors. This MARKED-
risk score is able to identify patients with very low, inter-
mediate, and excessive high risk for both short- and long-
term mortality.
Because the evaluation of dyspneic patients in the ED is
difficult and an accurate diagnosis cannot always be acquired
promptly, a non–diagnosis-specific risk score is helpful in
clinical practice. Especially for decision making in an acute
setting, short-term risk assessment is important. Several
biomarkers have been found useful for prognostification in
the evaluation of dyspneic patients, but single biomarkers
may not provide sufficient precision. Therefore, we hypoth-
esized that a multimarker approach could improve risk
stratification in this setting of a heterogeneous patient
Figure 1 90-Day Mortality Rate by Number of Elevated Biomark
The 90-day mortality rate by number of elevated biomarkers divided by (A) causepopulation. Thus, we examined 5 established biomarkers e(i.e., hs-cTnT, hs-CRP, Cys-C, Gal-3, and NT-proBNP)
for risk assessment in ED dyspnea.
cTnT is elevated in various chronic (25–27) and acute
(28–30) conditions such as heart failure, renal failure,
pulmonary embolism, and acute dyspnea and is undoubtedly
associated with adverse outcome in these settings and even
in the general population (31). CRP, a marker of inflam-
mation, is known to be elevated in both patients with acute
(13) and chronic (32,33) heart failure. CRP elevations in
heart failure are related to functional status and prognosis
(33,34). It was previously already shown that CRP has
additive prognostic value to other established biomarkers
such as NT-proBNP, hemoglobin, and BUN in patients
presenting with dyspnea to the ED (35,36). Gal-3, a marker
that is linked to fibrosis and inflammation, is involved in
heart failure, cancer, and renal disease and is predictive of
all-cause mortality in the general population (37). Although
its diagnostic role in HF is of limited value (12), Gal-3 is a
reasonable prognostic marker for short- to intermediate-
term outcome in HF (12,38), but less so for long-term risk
prediction (39,40). Cys-C, a marker for renal function that
strongly reflects glomerular filtration rate (41), is a strong
prognostic biomarker in acute HF independent of NT-
proBNP (42) and TnT (10), even in patients with normal
plasma creatinine (42). Cys-C concentrations are not only
indicative of renal function, but may also be elevated in
response to inflammation and underlying heart disease (43).
atriuretic peptides, mainly BNP and NT-proBNP, are
arkers that characterize cardiac wall stress and are
nea and (B) renal dysfunction. ADHF  acute decompensated heart failure.ers
of dyspstablished biomarkers for diagnosis and prognosis of
fi1674 Eurlings et al. JACC Vol. 60, No. 17, 2012
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dyspnea (28,45– 47). Nonetheless, the prognostic value of
NT-proBNP is very limited for short-term risk stratifi-
cation (9,14,15). Several other biomarkers have shown to
be superior for short-term risk stratification in acute HF
and ED dyspnea (13,15).
We found that all investigated biomarkers were predictive
of 90-day mortality and had incremental value on top of the
clinical risk model (Table 3). Gal-3, however, was dropped
from the final biomarker panel. This can at least partially be
explained by the existence of significant correlations be-
tween Gal-3 and other biomarkers (48). In line with our
Figure 2 Kaplan-Meier Curve for All-Cause Mortality
Kaplan-Meier curve for all-cause mortality by (A) number of elevated biomarkers a
Performance of Predictive Models for 90-Day MortalityTable 3 Performance of Predictive Models for 90-Day Mortality
Marker Wald OR (95% CI) Chi-S
Clinical risk factors† — —
 NT-proBNP 16.1 3.14 (1.80–5.49)
 hs-cTnT 25.3 4.33 (2.45–7.67)
 hs-CRP 29.9 4.69 (2.70–8.16)
 Cystatin-C 13.3 3.44 (1.77–6.67)
 Galectin-3 19.3 3.75 (2.08–6.78)
Clinical risk factors  3 markers¶ — —
For the Hosmer-Lemeshow (Hos-Lem) statistic, a p value close to 1 indicates excellent calibration.
BP110mmHg. ‡p 0.001 for comparison with clinical risk model. §p 0.01 for comparison wi
nal clinical model plus hs-cTnT, hs-CRP, and Cystatin-C.
AUC  area under the curve; IDI  integrated discrimination index; NRI  net reclassification index; ofindings, Gal-3 was not a significant predictor after the
inclusion of other predictors in a study of ambulatory HF
patients (39). Also, hs-CRP and Cys-C partially cover the
pathophysiological background of Gal-3, which may have
caused the exclusion of Gal-3. Furthermore, the prognostic
value of creatinine and BUN was attenuated in the presence
of Cys-C, which was previously also reported (42). Multi-
marker assessment thus revealed 4 markers as independent
predictors: hs-CRP, hs-cTnT, Cys-C, and NT-proBNP.
Importantly, the number of elevated markers was highly
predictive for 90-day mortality independent of the specific
combination of markers. This indicates that all 4 biomarkers
MARKED-risk score categories. MARKED  multimarker emergency dyspnea.
model C-Statistic AUC (95% CI) NRI IDI Hos-Lem
0.78 (0.73–0.83) — — 0.60
0.81 (0.76–0.86) 7% 4%‡ 0.23
0.82 (0.78–0.87) 18%§ 6%‡ 0.50
0.83 (0.78–0.88)§ 21%‡ 7%‡ 0.57
0.81 (0.77–0.86) 10% 2%§ 0.29
0.82 (0.77–0.87) 19%§ 4%‡ 0.62
0.86 (0.82–0.90)‡ 34%‡ 12%‡ 0.78
clinical model including age75 years, sex, history of heart failure, dyspnea NYHA IV, and systolic
al risk model. p 0.05 for comparison with clinical risk model. ¶Final prognostic model includingnd (B)quare
72.3
89.4‡
100.3‡
104.3‡
87.7‡
93.4‡
130.0‡
†Final
th clinicther abbreviations as in Tables 1 and 2.
a
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hypothesis on the independent value of biomarkers from
different pathophysiological pathways, which remained true
in subgroup analyses of renal function and acute HF
diagnosis. When further correcting the final biomarker
panel for clinical risk factors, NT-proBNP was excluded
from the final prediction model. Previous findings about the
inferior predictive value of NT-proBNP for short-term risk
prediction as discussed previously support the exclusion of
NT-proBNP from our final predictive model, although
correlation with other markers probably also plays a role
here. The final prediction model and the MARKED-risk
score thus included the biomarkers hs-CRP, hs-cTnT, and
Cys-C in addition to 5 clinical variables.
The MARKED-risk score is the first multimarker score
assessing short-term prognosis in ED patients with dys-
pnea. So far, no experience existed in the combined use of
hs-CRP, hs-cTnT, and Cys-C with regard to short-term
risk stratification in an unselected population with dyspnea
at the ED. One recent study combined BNP, cTnT, and
hs-CRP in acute HF patients and found a gradual increased
risk of 31-day mortality with an increasing number of
elevated biomarkers (4.3%, 10%, 20.9%, and 53.5% for 0, 1,
2, or 3 elevated biomarkers, respectively) (13). Other reports
Figure 3 90-Day Mortality Rate
per MARKED-Risk Score Point
Each bar resembles the patient group with a marked risk score category from
0 to 7. MARKED  Multi mARKer Emergency Dyspnea.
Mortality Rates by MARKED-Risk Score CategoriesTable 4 Mortality Rates by MARKED-Risk Score Categories
MARKED-Risk Score Category Admission
In-Hospital
Mortality M
Low, 3 points (n  287) 127 (44%) 1 (0%)
Intermediate, 3 and 5 points (n  219) 146 (67%) 11 (5%) 1
High, 5 points (n  97) 74 (76%) 18 (19%) 3
p value 0.001 0.001CV  cardiovascular; MARKED  Multi mARKer Emergency Dyspnea.on combined biomarkers in acute HF or ED dyspnea have
focused on long-term rather than short-term risk prediction
(8,11,36) or have focused mainly on the additive value of 1
marker on top of NT-proBNP (9,12). Moreover, early
differentiation of risk categories is lacking in most previous
studies, whereas our MARKED-risk score provides accu-
rate short-term as well as long-term stratification in distinct
risk categories, which is crucial for clinical decision making.
The apparent clinical prognostic uncertainty in our cohort—
reflected by the relative high admission rate in the low-risk
category and relative high discharge rate in the high-risk
category with similar mortality rates between admitted and
discharged patients—supports the need for accurate risk
stratification. Thus, although our study was not designed to
assess any therapeutic consequence, objective stratification
using the MARKED-risk score into very low, intermediate,
and high risk may help the treating physician at the ED to
decide on urge of intervention, admission, and timing of
re-evaluation. However, a clear-cut treatment advice cannot
be given based on our score.
We have chosen to use dichotomized values rather than
continuous variables to make the score useful for clinical
practice. We acknowledge that using cut-points can result
in loss of predictive power, but nonetheless our models and
score had excellent prognostic accuracy, discrimination, and
calibration. Other risk scores that are incorporated in
practice guidelines such as CHA2DS2-VASc, HAS-BLED,
nd Thrombolysis In Myocardial Infarction (3,49–51) con-
ist of single cut-point variables as well. Furthermore, the
redictive accuracy of our score is at least comparable—if
ot higher—to those of currently used risk scores in other
elds (AUC: MARKED 0.85, CHA2DS2-VASc 0.61,
HAS-BLED 0.72). Finally, we assessed the value of our
multimarker approach on top of the PRIDE mortality score
and found that adding hs-CRP, hs-cTnT, and Cys-C to the
PRIDE mortality score significantly improved the prognos-
tic accuracy in terms of AUC for both 90-day and 1-year
mortality. It should be noted that the PRIDE mortality
score was actually developed for 1-year outcome whereas we
focus on short-term outcome. Nevertheless, the AUC for
1-year mortality of the PRIDE mortality score in our cohort
(0.72, 95% CI: 0.68 to 0.77) was very comparable to the
AUC in PRIDE’s validation cohort (0.73, 95% CI: 0.64 to
0.82), indicating that our cohort is representative for cohorts
with dyspnea at the ED. Moreover, severity of dyspnea
indicated by New York Heart Association functional class in
y
ty
30-Day CV
Mortality
90-Day
Mortality
90-Day CV
Mortality
1-Year
Mortality
1-Year CV
Mortality
) 2 (1%) 5 (2%) 3 (1%) 24 (8%) 13 (5%)
) 14 (6%) 30 (14%) 22 (10%) 65 (30%) 47 (22%)
) 24 (25%) 43 (44%) 33 (34%) 56 (58%) 40 (41%)
1 0.001 0.001 0.001 0.001 0.00130-Da
ortali
4 (1%
7 (8%
2 (33%
0.00
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1
1
1
1
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the percentage of patients diagnosed with acute HF as well
as the 90-day and 1-year mortality rates were somewhat
higher in our cohort (6,52,53).
Study limitations. First, our study was performed in a
single-center ED. In addition, we did not externally validate
the MARKED-risk score. However, results were robust in
2 internal validation analyses (cross-validation and boot-
strapping), which are known to result in stable and nearly
unbiased estimates of performance (24,54) and our study is
comparable to other dyspnea cohorts as discussed. Second,
the number of patients was of moderate size. Taking this
together, it will be of interest to validate our findings in a
separate, preferably larger cohort. Finally, our study is not
able to directly assess the impact of the MARKED-risk
score on the management of patients. Therefore, the ther-
apeutic consequence of using the MARKED-risk score in
clinical practice for stratifying patients with dyspnea needs
prospective evaluation.
Conclusions
We present a simple, straightforward, non–diagnosis-
specific multimarker score for short-term risk stratification
in patients with dyspnea presenting to the ED, a population
with large diagnostic and prognostic uncertainty. This
multimarker approach that incorporates hs-cTnT, hs-CRP,
and Cys-C along with clinical risk factors (age 75 years,
dyspnea at rest, history of heart failure, and systolic blood
pressure 110 mm Hg) has incremental value beyond a
single-marker approach. Moreover, the MARKED risk
score is able to accurately identify patients with very low,
intermediate and especially those with excessive high risk
and may be useful in clinical practice.
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